Search research articles
Contact Us
Filters
Showing results (21-30 of 113) with videos related to
Page
of 12
Sort By:
Annals of the Rheumatic Diseases
|
January 1, 1994
Release of cartilage oligomeric matrix protein (COMP) into joint fluid after knee injury and in osteoarthritis
L S Lohmander, T Saxne, D K Heinegård
Annals of the Rheumatic Diseases
|
December 11, 2007
COMP: a candidate molecule in the pathogenesis of systemic sclerosis with a potential as a disease marker
R Hesselstrand, A Kassner, D Heinegård, et al.
Annals of the Rheumatic Diseases
|
August 1, 1990
Cytidine deaminase activity in synovial fluid of patients with rheumatoid arthritis: relation to lactoferrin, acidosis, and cartilage proteoglycan release
B Månsson, P Geborek, T Saxne, et al.
The Journal of Rheumatology
|
October 1, 1989
Cartilage derived proteoglycans in body fluids of children. Inverse correlation with age
T Saxne, F Castro, U Rydholm, et al.
Annals of the Rheumatic Diseases
|
June 18, 2003
Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritis
E Lindqvist, K Jonsson, T Saxne, et al.
Annals of the Rheumatic Diseases
|
August 1, 1980
Plasma levels of beta 2-microglobulin in rheumatoid arthritis
K G Sjöblom, T Saxne, F A Wollheim
British Journal of Rheumatology
|
September 1, 1992
Increased serum concentrations of cartilage oligomeric matrix protein. A prognostic marker in early rheumatoid arthritis
K Forslind, K Eberhardt, A Jonsson, et al.
British Journal of Rheumatology
|
April 1, 1992
Cytidine deaminase and lactoferrin in inflammatory synovial fluids. Indicators of local polymorphonuclear cell function?
P Geborek, B Månsson, G Hellmer, et al.
Osteoarthritis and Cartilage
|
May 6, 2017
Quantification of cartilage oligomeric matrix protein (COMP) and a COMP neoepitope in synovial fluid of patients with different joint disorders by novel automated assays
P Lorenzo, A Aspberg, T Saxne, et al.
Rheumatology (Oxford, England)
|
November 23, 2007
Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies
M Svenson, P Geborek, T Saxne, et al.
Page
of 12
Search research articles
Search
Showing results (21-30 of 113) with videos related to
Sort By:
Page
of 12
Annals of the Rheumatic Diseases
|
January 1, 1994
Release of cartilage oligomeric matrix protein (COMP) into joint fluid after knee injury and in osteoarthritis
L S Lohmander, T Saxne, D K Heinegård
Annals of the Rheumatic Diseases
|
December 11, 2007
COMP: a candidate molecule in the pathogenesis of systemic sclerosis with a potential as a disease marker
R Hesselstrand, A Kassner, D Heinegård, et al.
Annals of the Rheumatic Diseases
|
August 1, 1990
Cytidine deaminase activity in synovial fluid of patients with rheumatoid arthritis: relation to lactoferrin, acidosis, and cartilage proteoglycan release
B Månsson, P Geborek, T Saxne, et al.
The Journal of Rheumatology
|
October 1, 1989
Cartilage derived proteoglycans in body fluids of children. Inverse correlation with age
T Saxne, F Castro, U Rydholm, et al.
Annals of the Rheumatic Diseases
|
June 18, 2003
Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritis
E Lindqvist, K Jonsson, T Saxne, et al.
Annals of the Rheumatic Diseases
|
August 1, 1980
Plasma levels of beta 2-microglobulin in rheumatoid arthritis
K G Sjöblom, T Saxne, F A Wollheim
British Journal of Rheumatology
|
September 1, 1992
Increased serum concentrations of cartilage oligomeric matrix protein. A prognostic marker in early rheumatoid arthritis
K Forslind, K Eberhardt, A Jonsson, et al.
British Journal of Rheumatology
|
April 1, 1992
Cytidine deaminase and lactoferrin in inflammatory synovial fluids. Indicators of local polymorphonuclear cell function?
P Geborek, B Månsson, G Hellmer, et al.
Osteoarthritis and Cartilage
|
May 6, 2017
Quantification of cartilage oligomeric matrix protein (COMP) and a COMP neoepitope in synovial fluid of patients with different joint disorders by novel automated assays
P Lorenzo, A Aspberg, T Saxne, et al.
Rheumatology (Oxford, England)
|
November 23, 2007
Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies
M Svenson, P Geborek, T Saxne, et al.
Page
of 12